ArticleLancet regional health. Americas2025
Invasive pneumococcal disease in Argentina: a snapshot from a retrospective observational study on serotypes, antimicrobial resistance, and the potential impact of the COVID-19 pandemic (2018-2022).
Article in Lancet regional health. Americas, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Determinants of pneumococcal carriage by age in Africa (2000-2021): a systematic analysis.Frontiers in medicine · 2025Pooled it
- Antibiotic non-susceptibility associated serotypes of invasive pneumococcal disease - a nationwide population study from Switzerland, 2012-2022.Pneumonia (Nathan Qld.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Methods: We conducted a national laboratory-based surveillance study analysing 1304 Findings: A significant decrease in isolates was observed in 2020, followed by a resurgence beginning in 2021, peaking in 2022. The most prevalent serotypes in children (<5 years) over the past five years included 3 (11%; 54/494), 24F (8%; 39/494), 19A (7%; 35/494), 12F (6%; 30/494), and 14/23B (4%; 20/494). In adults (≥18 years), the leading serotypes were 3 (17%; 92/542), 8 (14%; 76/542), 7F (5%; 27/542), 9N (4%; 22/542), and 19A (4%; 22/542). Notably, antimicrobial resistance levels were significant, with children showing higher resistance rates (26% multidrug resistance) compared to adults (8%), Among PCV13 serotypes, 19A was predominantly associated with multidrug resistance, while non-PCV13 serogroup 24 was prevalent among resistant isolates. Interpretation: The fluctuations in serotype circulation, particularly among children under five, suggest evolving dynamics post-COVID-19. Although it remains uncertain if these changes are directly linked to the pandemic or reflect broader trends, the data highlight an urgent need for continued surveillance and potential adaptations in vaccination strategies. Funding: No funding was received for this study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.